Financhill
Back

TransMedics Group Quote, Financials, Valuation and Earnings

TransMedics Group Price Quote

$84.20
-3.04 (-3.48%)
(Updated: April 19, 2024 at 6:55 PM ET)

TransMedics Group Key Stats

Buy
69
TransMedics Group (TMDX) is a Buy

Day range:
$85.84 - $90.15
52-week range:
$36.42 - $99.63
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
11.74
P/B ratio:
20.8%

Volume:
640.4K
Avg. volume:
790K
1-year change:
22.55%
Market cap:
$2.9B
Revenue:
$241.6M
EPS:
$-0.77

How Much Does TransMedics Group Make?

Is TransMedics Group Growing As A Company?

  • What Is TransMedics Group's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 1.59%
  • What Is TransMedics Group's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

TransMedics Group Stock Price Performance

What Is TransMedics Group 52-Week High & Low?

TransMedics Group Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy TransMedics Group?

  • How Much Debt Does TransMedics Group Have?
    Total long term debt quarterly is $506.2M
  • How Much Cash Does TransMedics Group Have?
    Cash and short term investments quarterly total is $394.8M
  • What Is TransMedics Group’s Book Value Per Share?
    Book value per share is 4.20

Is TransMedics Group Cash Flow Positive?

  • What Is TMDX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$13M
  • What Is TransMedics Group’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $400.4M
  • What Is TransMedics Group’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$194M

TransMedics Group Return On Invested Capital

  • Is Management Doing A Good Job?
    TMDX return on invested capital is -5.17%
  • What Is TransMedics Group Return On Assets?
    ROA measures how assets are converting to revenues and is -4.72%
  • What Is TMDX Return On Equity?
    ROE is a measure of profitability and is -15.86%

TransMedics Group Earnings Date & Stock Price

TransMedics Group Competitors

TransMedics Group Dividend Yield

Data Unavailable

TransMedics Group Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 202.85%
Revenue: 158.72% 18.5%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 100.33
Upside from Last Price: 15.01%

Major Shareholders

  • How many TMDX shares are owned by institutional investors?
    58.2M TMDX shares are owned by institutional investors
  • How many TMDX shares are owned by insiders?
    968K TMDX shares are owned by insiders